Needham analyst Michael Matson has maintained their neutral stance on TFX stock, giving a Hold rating on December 7.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Matson has given his Hold rating due to a combination of factors surrounding Teleflex’s recent business decisions. The company announced agreements to sell its Acute Care and Interventional Urology business and its OEM business, expecting to receive approximately $1.8 billion after taxes from these transactions. This aligns with the lower end of previous valuation estimates, suggesting a cautious outlook.
Furthermore, Teleflex plans to utilize the proceeds for share repurchases or debt repayment, which could stabilize the company’s financial position but may not significantly enhance growth prospects. The projected earnings per share for the remaining company, RemainCo, indicate a price-to-earnings ratio that suggests the stock is fairly valued at present. These elements collectively contribute to a balanced perspective, justifying the Hold rating as the stock appears neither undervalued nor overvalued given current conditions.
In another report released on December 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $127.00 price target.